Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

The Pyruvate Kinase (PK) Activator AG-946 Improves PK Properties and Red Blood Cell (RBC) Characteristics upon Ex Vivo treatment of RBCs from Patients with Myelodysplastic Syndromes

Jonathan R.A. De Wilde, Titine J.J. Ruiter, Brigitte A. van Oirschot, Judith J.M. Jans, Lenny Dang, Megan Wind-Rotolo, Noortje Thielen, Wouter W. van Solinge, Anna van Rhenen, Richard van Wijk, Minke A.E. Rab

Blood (2023) 142 (Supplement 1): 3222.

https://doi.org/10.1182/blood-2023-185772

Published: 2023

Journal Articles

AG-946, an Activator of Pyruvate Kinase, Improves Ineffective Erythropoiesis in the Bone Marrow of Mouse Models of Myelodysplastic Syndromes

Alexandra Bunda, Hui Gao, Cecelia Burgwardt, Christy Ingersoll, Rohitash Jamwal, Lenny Dang, Megan Wind-Rotolo

Blood (2023) 142 (Supplement 1): 1854.

https://doi.org/10.1182/blood-2023-186197

Published: 2023

Journal Articles

AG-946 Normalizes Glycolysis and Improves Red Cell Indices in a Humanized Sickle Cell Mouse Model

Rohitash Jamwal, Lily C. Wain, Christopher Copeland, Penelope A. Kosinski, Megan Wind-Rotolo, Ilya Gertsman, William Eaton, David M Bodine, Lenny Dang, Swee Lay Thein

Blood (2022) 140 (Supplement 1): 950–951.

https://doi.org/10.1182/blood-2022-156591

Published: 2022

Journal Articles

A phase 1 dose escalation study of the pyruvate kinase activator mitapivat (AG-348) in sickle cell disease

Blood (2022) 140 (19): 2053–2062.

https://doi.org/10.1182/blood.2022015403

Published: 2022

Includes: Supplemental data

Journal Articles

Mitapivat (AG-348) Demonstrates Safety, Tolerability, and Improvements in Anemia, Hemolysis, Oxygen Affinity, and Hemoglobin S Polymerization Kinetics in Adults with Sickle Cell Disease: A Phase 1 Dose Escalation Study

Julia Z. Xu, Anna Conrey, Ingrid Frey, Eveline Gwaabe, Laurel A Menapace, Laxminath Tumburu, Maureen Lundt, Quan Li, Kristen Glass, Varsha Iyer, Heidi Mangus, Charles Kung, Lenny Dang, Penelope A. Kosinski, Peter Hawkins, Neal Jeffries, William Eaton, Swee Lay Thein

Blood (2021) 138 (Supplement 1): 10.

https://doi.org/10.1182/blood-2021-145398

Published: 2021

Journal Articles

Pharmacodynamic Effects of AG-946, a Highly Potent Next-Generation Activator of Pyruvate Kinase, in Ex Vivo Treatment of Red Blood Cells from Sickle Cell Disease Patients

Minke A.E. Rab, Myrthe J. Van Dijk, Jennifer Bos, Brigitte A. van Oirschot, Johan Gerrits, Penelope A. Kosinski, Charles Kung, Judith J.M. Jans, Eduard J. Van Beers, Lenny Dang, Richard van Wijk

Blood (2021) 138 (Supplement 1): 2029.

https://doi.org/10.1182/blood-2021-145374

Published: 2021

Journal Articles

Mitapivat Improves Transfusion Burden and Reduces Iron Overload in Thalassemic Mice

Alessandro Mattè, Penelope A. Kosinski, Enrica Federti, Lenny Dang, Angela Siciliano, Iana Iatcenko, Carlo Brugnara, Lucia De Franceschi

Blood (2021) 138 (Supplement 1): 2016.

https://doi.org/10.1182/blood-2021-153721

Published: 2021

Journal Articles

Decreased activity and stability of pyruvate kinase in sickle cell disease: a novel target for mitapivat therapy

Minke A. E. Rab, Jennifer Bos, Brigitte A. van Oirschot, Stephanie van Straaten, Penelope A. Kosinski, Victor Chubukov, Hyeryun Kim, Heidi Mangus, Roger E. G. Schutgens, Gerard Pasterkamp, Lenny Dang, Charles Kung, Eduard J. van Beers, Richard van Wijk

Blood (2021) 137 (21): 2997–3001.

https://doi.org/10.1182/blood.2020008635

Published: 2021

Includes: Supplemental data

Journal Articles

Phase 1 Multiple Ascending Dose Study of Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of Mitapivat (AG-348) in Subjects with Sickle Cell Disease

Blood (2020) 136 (Supplement 1): 21–22.

https://doi.org/10.1182/blood-2020-137716

Published: 2020

Journal Articles

The Pyruvate Kinase Activator Mitapivat Ameliorates Anemia and Prevents Iron Overload in a Mouse Model of Hereditary Spherocytosis

Alessandro Mattè, BSc,PhD, Wilson Anand, Enrica Federti, PhD, Charles Kung, PhD, Penelope A. Kosinski, MS, Veronica Riccardi, Iana Iatcenko, Lenny Dang, PhD, Christophe Leboeuf, Anne Janin, PhD, Carlo Brugnara, MD, Mohandas Narla, DSc, Lucia De Franceschi, MD

Blood (2020) 136 (Supplement 1): 29.

https://doi.org/10.1182/blood-2020-142232

Published: 2020

Journal Articles

Molecular Mechanisms Mediating Relapse Following Ivosidenib Monotherapy in Patients with IDH1 -Mutant Relapsed or Refractory Acute Myeloid Leukemia

Sung Choe, PhD, Hongfang Wang, PhD, Courtney D. DiNardo, MD MSc, Eytan M. Stein, MD, Stephane De Botton, Amir T. Fathi, MD, Martin S. Tallman, MD, Hagop M. Kantarjian, MD, Richard M. Stone, MD, Lynn Quek, MD PhD, Zenon Konteatis, PhD, Lenny Dang, PhD, Vickie Zhang, PhD, Hua Liu, PhD, Eyal C. Attar, MD, Bin Wu, PhD

Blood (2019) 134 (Supplement_1): 545.

https://doi.org/10.1182/blood-2019-122671

Published: 2019

Journal Articles

AG-348 enhances pyruvate kinase activity in red blood cells from patients with pyruvate kinase deficiency

Blood (2017) 130 (11): 1347–1356.

https://doi.org/10.1182/blood-2016-11-753525

Published: 2017

Includes: Supplemental data

Journal Articles

Characterization of Metabolic Response to AG-348, an Allosteric Activator of Red Cell Pyruvate Kinase, in Healthy Volunteers and Pyruvate Kinase Deficiency Patients

Victor Chubukov, Kendall Johnson, Penelope A Kosinski, Michelle Clasquin, Abhishek Jha, Hyeryun Kim, Thomas P Roddy, Elizabeth Merica, Ann J Barbier, Lenny Dang, Lee Silverman, Charles Kung

Blood (2016) 128 (22): 2452.

https://doi.org/10.1182/blood.V128.22.2452.2452

Published: 2016

Journal Articles

Effects of AG-348, a Pyruvate Kinase Activator, on Anemia and Hemolysis in Patients with Pyruvate Kinase Deficiency: Data from the DRIVE PK Study

Blood (2016) 128 (22): 402.

https://doi.org/10.1182/blood.V128.22.402.402

Published: 2016

Journal Articles

AG-348 Activation of Pyruvate Kinase in Vivo Enhances Red Cell Glycolysis in Mice

Charles Kung, Collin Hill, Yue Chen, Abhishek Jha, Penelope Kosinski, Michelle Clasquin, Yaguang Si, Hyeryun Kim, Jeff Hixon, Lenny Dang, Sam Agresta, Lee Silverman, Hua Yang

Blood (2014) 124 (21): 4010.

https://doi.org/10.1182/blood.V124.21.4010.4010

Published: 2014

Journal Articles

Small Molecule Activation Of Pyruvate Kinase Normalizes Metabolic Activity In Red Cells From Patients With Pyruvate Kinase Deficiency-Associated Hemolytic Anemia

Charles Kung, Ph.D., Jeff Hixon, Penelope Kosinski, Gavin Histen, Collin Hill, Yaguang Si, Andrew Kernytsky, Yue Chen, Ph.D., Byron DeLaBarre, Michelle Clasquin, Helen Ho, Furha I. Cossor, MD MS, Ellis J. Neufeld, MD, PhD, Frank Salituro, Janeta Popovici-Muller, Samuel Agresta, MD, Lee Silverman, Lenny Dang

Blood (2013) 122 (21): 2180.

https://doi.org/10.1182/blood.V122.21.2180.2180

Published: 2013

Journal Articles

Mutation Selective IDH Inhibitors Mediate Histone and DNA Methylation Changes

Blood (2012) 120 (21): 3509.

https://doi.org/10.1182/blood.V120.21.3509.3509

Published: 2012

Journal Articles

MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of NF-κB–dependent lymphoma

Michael A. Milhollen, Tary Traore, Jennifer Adams-Duffy, Michael P. Thomas, Allison J. Berger, Lenny Dang, Lawrence R. Dick, James J. Garnsey, Erik Koenig, Steven P. Langston, Mark Manfredi, Usha Narayanan, Mark Rolfe, Louis M. Staudt, Teresa A. Soucy, Jie Yu, Julie Zhang, Joseph B. Bolen, Peter G. Smith

Blood (2010) 116 (9): 1515–1523.

https://doi.org/10.1182/blood-2010-03-272567

Published: 2010

Includes: Supplemental data

Journal Articles

Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-κB pathways in subtypes of diffuse large B-cell lymphoma

Lloyd T. Lam, George Wright, R. Eric Davis, Georg Lenz, Pedro Farinha, Lenny Dang, John W. Chan, Andreas Rosenwald, Randy D. Gascoyne, Louis M. Staudt

Blood (2008) 111 (7): 3701–3713.

https://doi.org/10.1182/blood-2007-09-111948

Published: 2008

Includes: Supplemental data

Journal Articles

Ex Vivo Blockade of NF-[dappa]B Signaling in Alloreactive T Cells Prevents Murine Graft-Versus-Host Disease (GVHD).

Matthew J. O’Shaughnessy, Christine Vogtenhuber, Jonathon S. Serody, Raquel Sitcheran, Albert S. Baldwin, Lenny Dang, Bruce Jaffee, Bruce R. Blazar

Blood (2004) 104 (11): 3058.

https://doi.org/10.1182/blood.V104.11.3058.3058

Published: 2004

NARROW

The Pyruvate Kinase (PK) Activator AG-946 Improves PK Properties and Red Blood Cell (RBC) Characteristics upon Ex Vivo treatment of RBCs from Patients with Myelodysplastic Syndromes

AG-946, an Activator of Pyruvate Kinase, Improves Ineffective Erythropoiesis in the Bone Marrow of Mouse Models of Myelodysplastic Syndromes

AG-946 Normalizes Glycolysis and Improves Red Cell Indices in a Humanized Sickle Cell Mouse Model

A phase 1 dose escalation study of the pyruvate kinase activator mitapivat (AG-348) in sickle cell disease

Mitapivat (AG-348) Demonstrates Safety, Tolerability, and Improvements in Anemia, Hemolysis, Oxygen Affinity, and Hemoglobin S Polymerization Kinetics in Adults with Sickle Cell Disease: A Phase 1 Dose Escalation Study

Pharmacodynamic Effects of AG-946, a Highly Potent Next-Generation Activator of Pyruvate Kinase, in Ex Vivo Treatment of Red Blood Cells from Sickle Cell Disease Patients

Mitapivat Improves Transfusion Burden and Reduces Iron Overload in Thalassemic Mice

Decreased activity and stability of pyruvate kinase in sickle cell disease: a novel target for mitapivat therapy

Phase 1 Multiple Ascending Dose Study of Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of Mitapivat (AG-348) in Subjects with Sickle Cell Disease

The Pyruvate Kinase Activator Mitapivat Ameliorates Anemia and Prevents Iron Overload in a Mouse Model of Hereditary Spherocytosis

Molecular Mechanisms Mediating Relapse Following Ivosidenib Monotherapy in Patients with IDH1 -Mutant Relapsed or Refractory Acute Myeloid Leukemia

AG-348 enhances pyruvate kinase activity in red blood cells from patients with pyruvate kinase deficiency

Characterization of Metabolic Response to AG-348, an Allosteric Activator of Red Cell Pyruvate Kinase, in Healthy Volunteers and Pyruvate Kinase Deficiency Patients

Effects of AG-348, a Pyruvate Kinase Activator, on Anemia and Hemolysis in Patients with Pyruvate Kinase Deficiency: Data from the DRIVE PK Study

AG-348 Activation of Pyruvate Kinase in Vivo Enhances Red Cell Glycolysis in Mice

Small Molecule Activation Of Pyruvate Kinase Normalizes Metabolic Activity In Red Cells From Patients With Pyruvate Kinase Deficiency-Associated Hemolytic Anemia

Mutation Selective IDH Inhibitors Mediate Histone and DNA Methylation Changes

MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of NF-κB–dependent lymphoma

Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-κB pathways in subtypes of diffuse large B-cell lymphoma

Ex Vivo Blockade of NF-[dappa]B Signaling in Alloreactive T Cells Prevents Murine Graft-Versus-Host Disease (GVHD).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only